My group’s mission is to find new mechanisms and thus new therapeutic targets for vascular pathologies and chronic inflammatory conditions. We are particularly interested in disease specific approaches and solutions.
My laboratory projects aim at understanding the mechanisms underlying the pathological processes of cardiovascular diseases and, related to it, at understanding the process of chronic inflammation and control thereof. Our emphasis is on applications in cardiovascular pathologies and in chronic responses elicited by biomaterials, including biomedical devices and engineered tissue substitutes. In my laboratory we also interested in the role of the extracellular environment mechanics on the control of angiogenesis.
1992 EMBO Fellow, Institute of Molecular Biology, Austrian Academy of Sciences, Salzburg, Austria
1992-1993 Post-Doctoral fellow, University of Padova, Italy
1993-1995 Post-Doctoral fellow, Fred Hutchinson Cancer Research Center, Seattle, WA
1996-2000 Post-Doctoral fellow, University of Washington, Seattle, WA
Chair FASEB Summer Research Conference “Osteopontin and SIBLINGs”, 2012
2007-present American Heart Association, Vascular Biology-1, -2, -4 Study Sections
1993 University of Padova Fellowship for training abroad
1992 EMBO Short Term Fellowship
1992 Anna Villa Rusconi Fellowship
1991 Bayrofarm Italia Fellowship
Thomson KS, Korte FS, Giachelli CM, Ratner BD, Regnier M, Scatena M. Prevascularized Microtemplated Fibrin Scaffolds for Cardiac Tissue Engineering Applications. Tissue Eng Part A. 2013 Apr;19(7-8):967-77
Lund SA, Wilson CL, Raines EW, Tang J, Giachelli CM, Scatena M. Osteopontin mediates macrophage chemotaxis via ?4 and ?9 integrins and survival via ?4 integrin. J Cell Biochem. 2013 May;114(5):1194-202
Deuell KA, Callegari A, Giachelli CM, Rosenfeld ME, Scatena M. RANKL enhances macrophage paracrine pro-calcific activity in high-phosphate treated smooth muscle cells: dependence on IL-6 and TNF-?. J Vasc Res. 2012;49(6):510-21.
McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL have differential effects on angiogenesis in the rat aorta model. Angiogenesis. 2009;12(1):35-46.
McGonigle JS., Tae G, Stayton PS., Hoffman AS., Scatena M. Heparin regulated delivery of osteoprotegerin promotes vascularization of implanted hydrogels. Journal of Biomaterials Science: Polymer Edition, in press, 2007
Rice J, Courter DL, Giachelli CM, Scatena M. Molecular Mediators of alpha(v)beta(3)-Induced Endothelial Cell Survival.
J Vasc Res. 2006;43(5):422-436
Bennett BJ#, Scatena M#, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2006; 26(9):2117-24.
# Shared first authorship